TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01064934

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipid apheresis
Description: Weekly lipid apheresis procedure for lipoprotein(a) lowering

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care for maximum cardiovascular risk reduction (behavioural, exercise, nutrition, drugs, etc.)
Study: NCT04640649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm prediction
Description: Patients with early and intermediate AMD in at least one eye who are at risk of converting to wet AMD or GA expansion will be randomly assigned to a test group or control group. The test group will have their baseline data analyzed by an algorithm to predict the probability of conversion to wet AMD. If the probability is high for conversion at or before 3 months, patients will have earlier follow-up care than the control group (standard follow-up care every 6 months).
Study: NCT04203095

Intervention type: DIAGNOSTIC_TEST
Intervention: the level of plasma cfDNA CINs
Description: The extracted cfDNA from PB will be analyzed by UCAD to determine the level of CINs.
Study: NCT03554629

Intervention type: DEVICE
Group type: OTHER
Intervention: Capnography CO2 cannula sampling Flexiterline (CCSF) designs with supplemental O2
Description: Use of 8 post-market nasal CO2 cannula sampling filterlines; 4 nasal only sampling ports manufactured by Medtronic, Salter, Hudson/Teleflex and FlexiCare) and 4 post-market oral/nasal sampling ports manufactured by Medtronic, Salter, Dispo-Med and Westmed during scripted activity with supplemental O2.
Study: NCT02665767

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone-based Telesonography
Description: The 30 participating examiners were randomly divided into two groups. In phase one, group A performed ultrasonography under onsite mentoring and group B performed the same procedure under remote mentoring. Each examiner was randomly assigned one expert and three SPs for phase one. Four weeks later, they were partnered with the same expert and SPs to whom they had been assigned in phase one and performed the procedure under the other type of mentoring (phase two). The examination order of the SPs was randomly assigned by choosing a number between one and six (1: A-B-C, 2: A-C-B, 3: B-A-C, 4: B-C-A, 5: C-A-B, 6: C-B-A) in each phase.
Study: NCT03621631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimized Tai Chi intervention
Description: Optimized Tai Chi intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Tai Chi intervention
Description: Traditional Tai Chi intervention
Study: NCT02314780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heme arginate 3mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heme arginate 1mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02500810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monosialoganglioside
Description: 40mg in the vein on day 1 - day 8 of each 21 days cycle. Number of Cycles: 2 cycles.
Study: NCT04659577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT for panic and depression
Description: The most known type of CBT for treating PD consists of two major strategies: cognitive restructuring, and interoceptive and structured exposure to bodily sensations that have become associated with panic attacks. As for depression, the most known type of CBT for treating depression consists of two major strategies: cognitive restructuring, the relationship between thoughts and feelings, behavioural activation, sleep hygiene and relaxation. Each ICBT program includes six modules, containing psychoeducation, cognitive restructuring exposures, acceptance, and consolidation of gains and relapse prevention. The online modules include reading passages, worksheets, videos, and homework assignments. After completing each module participants practice related skills and complete homework assignments. The treatment is up to 16 weeks long; participants are encouraged to complete the treatment within this time period, and reminders are sent to monitor their progress
Study: NCT02083107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Comparison of different routes of administration of 400 micro gram misoprostol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Comparison of different routes of administration of 400 micro gram misoprostol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00898209

Intervention type: GENETIC
Intervention: protein expression analysis
Description: Blood and exhaled breath condensate will be collected.

Intervention type: GENETIC
Intervention: protein expression analysis
Description: Blood and exhaled breath condensate will be collected.

Intervention type: GENETIC
Intervention: proteomic profiling
Description: Blood and exhaled breath condensate will be collected.

Intervention type: GENETIC
Intervention: proteomic profiling
Description: Blood and exhaled breath condensate will be collected.

Intervention type: OTHER
Intervention: biologic sample preservation procedure
Description: Blood and exhaled breath condensate will be collected.

Intervention type: OTHER
Intervention: biologic sample preservation procedure
Description: Blood and exhaled breath condensate will be collected.

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Blood and exhaled breath condensate will be collected.

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Blood and exhaled breath condensate will be collected.

Intervention type: OTHER
Intervention: matrix-asst laser desorption/ionization time flight mass spectrometry
Description: Blood and exhaled breath condensate will be collected.

Intervention type: OTHER
Intervention: matrix-asst laser desorption/ionization time flight mass spectrometry
Description: Blood and exhaled breath condensate will be collected.

Intervention type: OTHER
Intervention: questionnaire administration
Description: Questionnaire will be completed.

Intervention type: OTHER
Intervention: questionnaire administration
Description: Questionnaire will be completed.
Study: NCT04067934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jumping Exercise programme
Description: Four weeks of three jumping-based exercise sessions per week. These sessions will involve basic jumping movements, with approximately 50-100 jumps per session; incorporating 20-30 minutes of exercise.
Study: NCT03433963

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Arg supplement
Description: L-Arg supplement will be prepared as pills, administered 9g each day in 3 times for 2 weeks.
Study: NCT01350284

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cinnamon
Description: acute oral administration of 3 g cinnamon
Study: NCT03433963

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be prepared as pills (the same size, color and shape as of L-Arg), administered 3 times daily for 2 weeks.
Study: NCT01350284

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo control
Description: 3 g wheat flour (placebo)- separated by 28 days from cinnamon intervention
Study: NCT02398305

Intervention type: DEVICE
Group type: OTHER
Intervention: TR Band standard
Description: Diminishing the air pressure in the TR Band following standard protocol

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TR Band Quick
Description: Diminishing the air pressure in the TR Band following a faster protocol
Study: NCT01320059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-PEG6-IPQA
Description: Radioactive injection (PET imaging agent) given by vein before PET scans.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Description: 3 PET scans performed after injection and positioning CT. Imaging should take about 3 hours.
Study: NCT02497924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: GBT440 capsules followed by single dose of \[C14\] GBT440 oral suspension
Study: NCT02158052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus starting on Day -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Equine Anti-thymocyte globulin
Description: 20 mg/kg IV on Days -3, -1, +1, +3

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Kidney transplant from a related donor
Description: On Day 0 the renal transplant is performed according to standard surgical techniques.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplant from a related donor
Description: On Day 0 the renal transplant is performed according to standard surgical techniques.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone marrow transplant from a related donor
Description: Donor bone marrow (\> 2 x 10e8 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation 400 centigray (200 cGy X 2)
Description: On transplant day -1
Study: NCT00988078

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule (without biologic action) administered three times a day for six months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500mg three times a day for six months
Study: NCT00697931

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant MPL- adjuvanted hepatitis B vaccine
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: Intramuscular injection, 3 doses
Study: NCT03123601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Risk sign displays
Description: Set of sign displays designed to communicate fall, dehydration and pulmonary aspiration risks and reflect on tailored interventions to manage these events in nursing homes. Risk sign displays are:~* Small, lightweight rubber coloured bracelets with phrases related with the different risks: prevent rather than fall, contain to protect, drink to hydrate and avoid choking.~* Small and coloured signposts next to head of patients bed that are believed to offer some key advantages and increase technically the quality of immediate communication of information and data regarding procedures. It is expected to have greater subject compliance once they will have discrete messages with thoughtful design and colour.
Study: NCT04497064

Intervention type: OTHER
Intervention: survey
Description: survey asking questions regarding breakfast habits and composition, sports nutrition knowledge and exercise habits

Intervention type: OTHER
Intervention: survey
Description: survey asking questions regarding breakfast habits and composition, sports nutrition knowledge and exercise habits
Study: NCT00543712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO95780
Description: Intravenous repeating dose
Study: NCT01015560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CCR2 monoclonal antibody MLN1202

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT04070560

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intact cord (≥ 180 seconds) resuscitation
Description: Resuscitation performed in near proximity to the mother with umbilical cord uncut

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early (≤ 60 seconds) cord clamping
Description: Resuscitation performed at a designated area after umbilical cord is cut
Study: NCT04379063

Intervention type: OTHER
Intervention: COVID-19 pandemic
Description: Currently practicing during the COVID-19 pandemic
Study: NCT02750774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-glycemic index group
Description: The dietary intervention consisted of the prescription of a Mediterranean style, low-glycaemic, low-fat, exchange diet (3 main meals and 3 snacks) with a total intake of 1500 kcal/day. In light of the PA, the dietitian adds 200 kcal/day for obese, 300 kcal/day for overweight women. The diet had a target macronutrient composition of 55% carbohydrates (80% complex carbohydrates with a low glycaemic index and 20% simple carbohydrates), 20% protein (50% animal and 50% vegetable) and 25% fat (12% mono-unsaturated, 7% polyunsaturated and 6% saturated) with moderately low saturated fat levels. The daily intake of carbohydrates was at least 225 g/day. The exercise intervention was focused on developing a more active lifestyle. The PA prescription is consistent with recommendations by the ACOG and ACSM for pregnant women. The talk test (being able to maintain a conversation during activity) was suggested to monitor the exercise intensity.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care Group
Description: Women randomized to the Standard Care Group received general information about healthy lifestyle during pregnancy, according to the Guidelines
Study: NCT02631551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSP 301 NS
Description: FDC of olopatadine HCl and mometasone furoate: 2 sprays in each nostril twice daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine HCl NS
Description: 2 sprays in each nostril twice daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate NS
Description: 2 sprays in each nostril twice daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSP 301 Placebo NS
Description: 2 sprays in each nostril twice daily for 14 days
Study: NCT04538937

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT03445884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-E[c(RGDyK)]2
Description: 200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 68Ga-NODAGA-E[c(RGDyK)]2
Description: 200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV.
Study: NCT00000145

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidants
Description: 500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene
Study: NCT02338635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: Inhibition of ER stress (Ursodeoxycholic Acid)
Study: NCT00000145

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: 80 milligrams zinc oxide; 2 milligrams of cupric oxide

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidants and zinc
Description: 500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene; 80 milligrams zinc oxide; 2 milligrams of cupric oxide
Study: NCT03149809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin
Description: Antimuscarinic bladder relaxant, antagonizes bladder muscarinic receptors

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle exercise-based behavioral therapy
Description: Multicomponent intervention including fluid management, constipation management and behavioral techniques incorporating pelvic floor muscle-exercise based urge suppression and self-monitoring to reduce overactive bladder symptoms
Study: NCT00839904

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: two supervised, 60-minute weekly exercise sessions + instructions to perform additional physical activities throughout the day
Study: NCT06114316

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: individualized nursing interventions based on the Roy Adaptation Model /experimental
Description: The personal behaviors that could be related to recurrence (physiological, self-concept, role function, and mutual commitment) and the stimuli that caused recurrence (focal and affecting) were assessed, objectives were determined, and nursing interventions were carried out in line with these objectives. The interventions planned for diagnosing ineffective coping were selected according to the patients' needs among the support coping interventions under the title of the behavioral area in the Nursing Intervention Classification (NIC). A total of 10 individual interviews were made twice a week for about 45 to 60 minutes. The interviews were evaluated by determining the area specific Nursing outcome classification (NOC) (self respect, social support, mood management, role performance).
Study: NCT01882205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual chromoendoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual chromoendoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual chromoendoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chromoendoscopy
Description: Panchromocolonoscopy with methyleen blue 0.1%

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chromoendoscopy
Description: Panchromocolonoscopy with methyleen blue 0.1%

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chromoendoscopy
Description: Panchromocolonoscopy with methyleen blue 0.1%
Study: NCT04764643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine solution
Description: use N-acetylcysteine solution to alleviate esophageal irritation caused by Lugol's chromoendoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium thiosulfate solution
Description: use sodium thiosulfate solution to alleviate esophageal irritation caused by Lugol's chromoendoscopy
Study: NCT02808078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait training with augmented reality
Description: 20 sessions (30 min. duration) over 4 weeks of gait training with augmented reality.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard training
Description: 20 sessions (30 min. duration) over 4 weeks of gait training without augmented reality.
Study: NCT03505034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells
Description: Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1\*10\^6 cells/kg, once a month for 4 months
Study: NCT02054585

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 0.9%
Description: Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid.
Study: NCT05170061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 160 mg PO daily for 1 week followed by 320 mg daily for 3 weeks, followed by 1 week down-titration to 160 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Nebivolol 20 mg daily for 1 week followed by 40 mg daily for 3 weeks, followed by 1 week down-titration to 20 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol/valsartan
Description: Valsartan/Nebivolol, 160/20 mg daily for 1 week followed by 320/40 mg daily for 3 weeks, followed by 1 week down-titration to 160/20 mg daily
Study: NCT00607347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Oral Glucose Tolerance Test
Study: NCT04490590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide+ Etoposide
Description: Patients will receive the treatment of and chidamide and etoposide capsule, and those who have achieved CR（complete response）or PR（partial response）or SD(stable disease)will continue the treatment.
Study: NCT01745731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.
Description: Proceeds to selective application of stem cells in the portal branches of segments II and III as 10 ml aliquots of taking a time of 4 minutes between each application.
Study: NCT02540928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 319 hydrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03930290

Intervention type: DIAGNOSTIC_TEST
Intervention: Vaginal tactile imager
Description: Vaginal elasticity evaluation by vaginal tactile imaging analysis.
Study: NCT01290029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Single, oral dose of 0.25 mg/kg cinacalcet
Study: NCT02609347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy Group
Description: The manual therapy intervention will be based on the typed of fracture the patient sustained, and their limitations in joint mobility.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: The sham intervention will consist of soft tissue mobilization and Grade I mobilization at the proximal tib/fib joint.
Study: NCT00472810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ologen collagen matrix in glaucoma filtering surgery
Description: If ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMC in glaucoma filtering surgery
Description: If mitomycin -C is applied, a single cellulose sponge soaked with MMC (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
Study: NCT03955796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrophobic IOL
Description: RayOne Hydrophobic Aspheric, hydrophobic IOL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-hydrophobic IOL
Description: RayOne Aspheric, non-hydrophobic IOL
Study: NCT03208777

Intervention type: GENETIC
Intervention: taking blood samples
Description: taking blood samples and measure telomeric abnormalities

Intervention type: GENETIC
Intervention: taking blood samples
Description: taking blood samples and measure telomeric abnormalities

Intervention type: GENETIC
Intervention: taking blood samples
Description: taking blood samples and measure telomeric abnormalities
Study: NCT02984202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auditory midbrain implant (AMI)
Study: NCT01467726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velusetrag
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velusetrag
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules